Monday, March 23, 2026

Latest

Datametrex Secures Rights To Sell And Distribute Rapid COVID-19 Antigen Test Kits

Datametrex AI (TSXV: DM) this morning announced that it has secured the rights to sell and distribute a rapid antigen detection kit from South Korean manufacturer PCL Inc. The main benefit of the test is that with 97% accuracy, they produce results in as little as 5 to 10 minutes with no extra equipment being required for the consumer.

Datametrex AI's Logo

The test hosts advantages over others on the market solely as a result of the rapid testing nature of the product, combined with the lack of additional equipment being needed to conduct the test. The test is a method of measuring the presence of a COVID-19 infection via an in-vitro diagnostic medical device. It detects antigen of the SARS-CoV-2 virus from a persons oropharyngeal and nasopharyngeal secretions. Like a simple pregnancy test, if antigens are found a colored line appears in the T line area.

It’s said that the test has a clinical sensitivity, i.e., the ability to confirm the actual positive of the approved person, of 100%, and the clinical specificity, i.e the ability to confirm the actual negative of the negative person, of 97.78%. The antigen test has been awarded numerous certifications, including CE, Korea FDA, UNGM and more. It’s also been approved by the EU, Qatar, United Arab Emirates, India, Russia, Ecuador, Guatemala and Colombia.

“According to the manufacturer, PCL, this test can detect antigens of COVID-19 from a swab in the nose or throat and provide results in 10 minutes with over 97% accuracy. These almost-instant kits can be easily used at home. With the rise of cases in the United States and throughout the world, we at Datametrex believes it is critical to test and protect.”

Marshall Gunter, CEO of Datametrex

The strong benefit of the instant antigen kits that require no additional equipment, is that they can be conducted at home easily, with nearly instant results. This eliminates excessive wait times as high as 3-5 days or more previously experienced by individuals that have had other forms of COVID-19 tests performed.

Datametrex AI last traded at $0.15 on the TSX Venture.


FULL DISCLOSURE: DataMetrex AI Limited is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover DataMetrex AI Limited on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why the Market May Be Misreading Iran | David Woo

Why US Fertilizer Supply Could Matter a Lot More Now | Pat Varas – Sage Potash

Roscan Gold: Mali Discount Hits Kandiole PEA

Recommended

CBS News Cuts Staff and Shuts Radio Network in Early Bari Weiss Era

Steadright Closes Out Financing, Raising $1.6 Million For Moroccan Strategy

Related News

Retail Landlords Begin Issuing Default Notices to Tenants

It appears the economic implication stemming from the coronavirus pandemic keep mounting. As retailers were...

Tuesday, May 26, 2020, 05:03:00 PM

Rental Car Firms Cancel New Vehicle Orders, Struggle To Store Fleet

Rental car firms have begun cancelling new vehicle orders from manufacturers across the US as...

Saturday, May 9, 2020, 01:39:00 PM

World Health Organization Warns of Dangerous Second Phase of COVID-19, Cases Continue to Rise Across US States

On Friday, the World Health Organization (WHO) issued a grim statement regarding the coronavirus crisis....

Sunday, June 21, 2020, 06:21:00 PM

Datametrex Officially Enters Beta Phase For Telemedicine App

Datametrex AI (TSXV: DM) is one step closer to offering a full service telemedicine app....

Wednesday, October 20, 2021, 07:37:13 AM

Toronto Pearson Airport Reports Further Layoffs, Anticipates Pre-Pandemic Level Recovery to Take 3-5 Years

Much like the stagnant demand for air travel south of the border, Canadian airports have...

Wednesday, July 15, 2020, 04:41:00 PM